small molecule

ROMVIMZA

VIMSELTINIB

Loss of exclusivityApril 2045latest FDA-listed patent expiry

CompanyDeciphera Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand name	ROMVIMZA
Active ingredient	VIMSELTINIB
Strength	14MG
Dosage form	CAPSULE
Route	ORAL
Modality	Small molecule
FDA approval	February 2025
Marketing status	RX

Listed patents

Patent	Expires	Type
12509443	April 2045	product
12551483	December 2044	product
12528787	December 2044	substance, product
12643883	December 2044	substance, product
12447149	December 2044	product
12617775	December 2044	substance, product
11679110	February 2040	use U-4145
11103507	February 2040	use U-4145
12285430	December 2039	use U-4145
12485120	December 2039	use U-4145
12582655	December 2039	use U-4145
9181223	March 2034	substance, product

Regulatory exclusivity

Code	Expires
NCE	February 2030

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Drug detail

Listed patents

Regulatory exclusivity

More from Deciphera Pharmaceuticals